Germline BCL-2 sequence variants and inherited predisposition to prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 3, 2006, Pages 284-292

  Kidd, L R ^a   Coulibaly, A ^b   Templeton, T M ^a   Chen, W ^b   Long, L O ^b   Mason, T ^b   Bonilla, C ^b,c   Akereyeni, F ^b   Freeman, V ^d,e   Isaacs, W ^f   Ahaghotu, C ^b,g   Kittles, R A ^b,c,g  

^a University of Louisville School of Medicine   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

Apoptosis; Bcl 2; Prostate cancer

Indexed keywords

PROTEIN BCL 2;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA SEQUENCE; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FAMILY HISTORY; GENETIC VARIABILITY; GERM LINE; HAPLOTYPE; HUMAN; INHERITANCE; JAMAICA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SEQUENCE ANALYSIS;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; INHERITANCE PATTERNS; JAMAICA; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OPEN READING FRAMES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGULATORY ELEMENTS, TRANSCRIPTIONAL; VARIATION (GENETICS);

EID: 33748280472     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500884     Document Type: Article

References (43)

1. American Cancer Society. Factors that influence cancer rates. Cancer Fact and Figures 2005 2005, 59-60.
2. Glover Jr FE, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T et al. The epidemiology of prostate cancer in Jamaica. J Urol 1998; 159: 1984-1986.
3. Tang DG, Porter AT. Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 1997; 32: 284-293.
4. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc Natl Acad Sci USA 1987; 84: 1329-1331.
5. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res 2001; 32: 175-185.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
7. Wang K, Gross A, Waksman G, Korsmeyer SJ. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol 1998; 18: 6083-6089.
8. Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002; 20: 63-74.
9. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
10. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430.
11. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 2000; 9: 2528-2534.
12. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997; 275: 983-986.
13. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996; 28: 98-106.
14. Johnson Ml, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation. Prostate 1998; 37: 223-229.
15. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Ross JS. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004; 128: 39-43.
16. Hering FL, Lipay MV, Lipay MA, Rodrigues PR, Nesralah LJ, Srougi M. Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score. Sao Paulo Med 12001; 119: 138-141.
17. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34: 251-258.
18. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390-400.
19. Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 1997; 32: 9-15.
20. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996; 56: 5594-5599.
21. Lang G, Gombert WM, Gould HJ. A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology 2005; 114: 25-36.
22. Grabe N. AliBaba2: Context specific identification of transcription factor binding sites. In Silico Biol 2002; 2: S1-S15.
23. Kittles RA, Young D, Weinrich S, Hudson J, Argyropoulos G, Ukoli F et al. Extent of linkage, disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: Implications for the prostate cancer risk. Cancer Risk 2001; 109: 253-261.
24. Panguluri R, Chen W, Kittles R. SNP genotyping of candidate genes for complex diseases using pyrosequencing. Am Biotechnol Lab 2002; 20: 30-34.
25. Satten GA, Epstein MP. Comparison of prospective and retrospective methods for haplotype inference in case-control studies. Genet Epidemiol 2004; 27: 192-201.
26. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998; 110: 443-449.
27. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995; 1: 1103-1110.
28. Anton RC, Brown RW, Younes M, Gondo MM, Stephenson MA, Cagle PT. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. Hum Pathol 1997; 28: 1079-1082.
29. Akita H, Katabami M, Hommura H, Fujioka Y, Katoh H, Kawakami Y Bcl-2 expression in non-small cell lung cancers: Higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 1999; 56: 259-264.
30. Meterissian SH, Kontogiannea M, Al-Sowaidi M, Linjawi A, Halwani F, Jamison B et al. Bcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann Surg Oncol 2001; 8: 533-537.
31. Nakamura T, Nomura S, Sakai T, Nariya S. Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. Hum Pathol 1997; 28: 309-315.
32. Stattin P. Prognostic factors in prostate cancer. Scand J Urol Nephrol Suppl 1997; 185: 1-46.
33. Lu QL, Abel P, Foster CS, Lalani EN. bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110.
34. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
35. Kallakury BV, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod Pathol 1996; 9: 41-47.
36. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-1516.
37. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
38. Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002; 21: 3898-3908.
39. Xie W, Wong YC, Tsao SW. Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. Prostate 2000; 44: 31-39.
40. Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anagnostopoulou I, Biddolph S et al. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 1996; 179: 10-14.
41. Ter B, Smedts F, Kuijpers J, Jeunink M, Trimbos B, Ramaekers F. BCL-2 immunoreactivity increases with severity of CIN: A study of normal cervical epithelia, CIN, and cervical carcinoma. J Pathol 1996; 179: 26-30.
42. Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: Immunohistochemical comparative analysis. Growth Factors 2000; 18: 135-146.
43. Chi KN, Gleave ME. Antisense approaches in prostate cancer. Expert Opin Biol Ther 2004; 4: 927-936.